MenABCWY vaccine

COMBINATION_PRODUCT3 trials

Sponsors

GlaxoSmithKline

Conditions

Meningitis, Meningococcal

Phase 2

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

CompletedNCT03587207

GlaxoSmithKlineMeningitis, Meningococcal

Start: 2018-07-09End: 2018-12-19Updated: 2020-02-12

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

Active, not recruitingNCT05087056

GlaxoSmithKlineMeningitis, Meningococcal

Start: 2021-11-18End: 2027-03-10Updated: 2026-04-13

Phase 3

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

CompletedNCT04707391

GlaxoSmithKlineMeningitis, Meningococcal

Start: 2021-01-25End: 2023-09-29Updated: 2024-07-03

Related Papers

Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized Controlled Clinical Study

Clinical Infectious Diseases2024-12-263 citations

Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.

2021-11-1712 citations